Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Risk of second primary malignancy following chimeric antigen receptor T-cell therapy: A real-world cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

APA. PhillippiHLHongtao Liu

Discussion

Loading...

Member takes

Overview

Cohort study reveals increased second primary malignancy rates in patients post CAR-T therapy, indicating the need for long-term hematologic follow-up.

Key Points

  • Patients treated with CAR-T therapy exhibited a significantly high risk of therapy-related myeloid malignancies after treatment.
  • The study identified higher incidences of acute myelogenous leukemia and myelodysplastic syndrome in the CAR-T group compared to the non-CAR-T group.
  • Retrospective cohort analysis utilized propensity score matching to balance baseline characteristics between treatment groups.
  • Improved long-term follow-up care is necessary to monitor for early signs of secondary malignancies in CAR-T therapy patients.

Cite This Study

Phillippi et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2e0https://doi.org/10.1182/blood-2025-7667
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk of second primary hematological malignancy post chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma: Propensity-matched analysis using trinetx database2025
  2. 2Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival2025
  3. 3Risk of venous and arterial thromboembolic events following CAR-T therapy in relapsed or refractory non-Hodgkin lymphoma: A propensity-matched multicenter analysis.2025
  4. 4Burden and outcomes of CAR T-cell therapy toxicities in DLBCL, multiple myeloma, and B-ALL: A nationwide analysis2025
  5. 5Feasibility, outcomes and challenges of CAR-T cell therapy as advanced or earlier line of treatment for B-cell non-Hodgkin lymphomas: A multicenter national study2025